SecBot SecBot
Insider Cluster (2 insiders) ·Filed Aug 11, 2026

MIRM

Mirum Pharmaceuticals, Inc.
BEARISH
Impact 5/10
Horizondays Processed3mo ago
Insider cluster: 2 insiders, $1.3M total
Actionable Insight ▼ Bearish

CEO selling following an earnings miss and pipeline delay is a cautionary signal, but the dollar amount is small relative to market cap. Monitor for additional insider sales in the next 2 weeks; if C-suite selling continues, it would reinforce the bearish read. The volixibat Phase 3 requirement and timeline, not insider trades, remain the primary catalyst for the stock.

DirectionBearish
Confidencemedium
Horizondays

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$98.97
T+0 close · Aug 11, 2026 · via day close
Latest settled
−2.02%
T+60 · $96.97
Vs SPY
+2.86%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 12 $98.97entry
  2. T+1 · 3mo ago −0.20%α −0.90% · $98.77
  3. T+5 · 3mo ago +3.30%α +3.75% · $102.24
  4. T+20 · 2mo ago +1.66%α +3.55% · $100.61
  5. T+60 · 12d ago −2.02%α +2.86% · $96.97
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CEO Christopher Peetz executed a cluster of open-market sales totaling ~$1.98M, including a single-day sale of 11,683 shares at ~$1.15M, alongside derivative exercises. The sales follow a Q2 earnings miss and volixibat pipeline delay reported 6 days prior. While the dollar amount is modest relative to Mirum's $6.4B market cap (0.03%), the CEO's status amplifies the signal, particularly given the negative earnings surprise and pipeline setback disclosed in the same window.

Key Financial Metrics

Direction
selling
Total Value
$2.0M
Insiders
2

Key Facts

  • CEO Peetz sold ~$1.98M in open-market sales on 2026-08-10, the largest being 11,683 shares at ~$1.15M
  • Total cluster value of ~$2.32M (including Jolanda Howe's $194K sale) represents ~0.04% of Mirum's $6.4B market cap
  • Sales occurred 6 days after Q2 2026 earnings (GAAP EPS -$1.06 vs -$0.75 consensus) and a volixibat NDA delay to H1 2027
  • Peetz also exercised 40,000 derivative shares (20,000 at $2.936; 20,000 at $0), these are non-cash events
  • Prior insider activity (30d): 4 sells totaling $2.2M at higher prices, suggesting a selling pattern

Financial Impact

CEO open-market sales of ~$1.98M; cluster total ~$2.32M, 0.04% of market cap

insider ownershipdilution from derivative exercise

Risk Factors

  • Further insider sales could signal deteriorating management confidence
  • Q2 EPS miss and volixibat delay already pressured sentiment; additional negative news could compound
  • CEO derivative exercises (40,000 shares) will add to share count, though at minimal cost basis

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-MIRM-1786485690367

US Market Status

Market Closed · Opens in 8h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 11, 2026